Archive
1250 articles, sorted by publication time.
Among the first 40 patients who completed open-label treatment in the CAPTIVATE trial, 30 met the prespecified response criteria; the figure exceeded the company’s threshold but cannot yet substitute for randomized, placebo-controlled relapse results.
The FDA plans to introduce Qualified Research Institutions and rolling review, allowing some regulatory, ethics, and trial-site preparation work to proceed in parallel; the real test, however, is whether shorter reviews can translate into participants receiving their first treatment dose sooner.
A small number of patients who cannot participate in clinical trials and meet strict medical criteria may apply through their physicians for pre-approval expanded access; the arrangement follows a special individual case and also highlights the difficult balance between urgent need and equitable access.
Just 68 days elapsed between the World Health Organization’s emergency declaration and the first volunteer’s vaccination; this Phase 1 trial will first assess safety and immune response, while crucial hurdles remain before the vaccine can be shown to prevent infection in outbreak areas.
Novo Nordisk’s IL-6 antibody showed the expected biological activity in more than 6,300 high-risk patients but did not reduce the risk of cardiovascular death, myocardial infarction, or stroke, introducing uncertainty into the drug strategy that suppressing inflammation can protect the heart.
An experiment involving 623 members of the general public and 153 primary care physicians showed that diagnostic AI designed to account for fairness across skin tones can improve overall performance; however, when the model is wrong, fluent LLM explanations are the most likely to steer non-expert users toward the wrong answer.
The startup, co-founded by gene-editing pioneers, initially sought to turn customized therapies for individual patients into a replicable platform. It is now laying off staff and discontinuing its core program, exposing the difficult gap between technical breakthroughs and a viable business model for ultra-rare diseases.
Cases and deaths have climbed rapidly within weeks, while no approved vaccine or specific treatment exists for this virus type; the front line of the outbreak response has now also become a critical testing ground for candidate drugs and post-exposure prevention strategies.
The next round of the U.S. medical device user fee program has entered public debate; the draft not only calls for shorter review cycles, but also seeks to incorporate early consultation, multinational collaboration, and reimbursement discussions into the path to market.
The research team had the same model process medical images, electrocardiographic signals, and clinical text, demonstrating transferability in cross-dataset testing. However, its leading performance on retrospective benchmarks remains separated from real-world clinical decision-making by critical gaps.
The U.S. FDA is seeking clinically interpretable digital measurement methods through a cooperative research program, with the aim of bringing wearable devices and contactless sensors into drug trials; however, the scale of the two awards also shows that this remains an early-stage effort to establish evidence standards.
A comparison spanning 41 cancer pathology tasks shows that models trained specifically for pathology images perform strongly overall, but there is no single winner; rankings change outside familiar data, and model size is not a reliable guide for selection.